

39. The isolated nucleic acid molecule of claim 1, wherein said nucleic acid molecule encodes a polypeptide comprising a sequence substantially equivalent to SEQ ID NO:2.

40. A recombinant vector comprising the nucleic acid molecule of claim 39.

41. A genetically engineered cell comprising the recombinant vector of claim 40.

42. An isolated nucleic acid molecule comprising a sequence that has at least about 90% sequence identity to a polynucleotide comprising the sequence of nucleotides ranging from nucleotide 1 to nucleotide 2100 of SEQ ID NO:1.

43. A recombinant vector comprising the nucleic acid molecule of claim 42.

44. A genetically engineered cell comprising the recombinant vector of claim 43.

45. An isolated nucleic acid molecule comprising a sequence that has at least about 95% sequence identity to a polynucleotide comprising the sequence of nucleotides ranging from nucleotide 1 to nucleotide 2100 of SEQ ID NO:1.

46. A recombinant vector comprising the nucleic acid molecule of claim 45.

47. A genetically engineered cell comprising the recombinant vector of claim 46.

REMARKS

Reconsideration of the application in view of the above amendments and the following remarks is respectfully requested.

After Applicants' election with traverse, claims 1-3 were pending in the application. Applicants have added new claims 39-47. Therefore, claims 1-3 and 39-50 are now pending in the application. No new matter has been added by the claim amendment or the new claims. Support for the new claims is found throughout the specification. See, for example, the section entitled "Polynucleotides and Nucleic Acids of the Invention."